# Aldara for the Treatment of Large and/or Multiple sBCC

> **NCT00189280** · PHASE3 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 111 (actual)

## Conditions studied

- Carcinoma, Basal Cell

## Interventions

- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT00189280
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189280, "Aldara for the Treatment of Large and/or Multiple sBCC". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00189280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*